ImmunityBio's Unpriced Moonshots

Seeking Alpha published an article focusing on ImmunityBio (NASDAQ: IBRX), highlighting that none of the company's 'moonshots' are currently priced into its stock valuation. The report suggests that the market is overlooking the potential value embedded in these ambitious projects.

Why it matters: This disconnect could present a significant opportunity for long-term investors willing to bet on the company's high-risk, high-reward pipeline.